The independent source for health policy research, polling, and news.
1 - 20 of 1,298 Results
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren't properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
The data behind alcohol-related traffic deaths is well studied. Less understood is the toll of vehicle deaths involving drugs or a combination of drugs and alcohol. Attempts to fix that have been stymied by federal budget and staffing cuts.
New ethics disclosures show the president invested in Eli Lilly and a company that manufactures injectable devices as his health agencies implemented policies that benefited them.
KFF Health News journalists made the rounds on national media recently to discuss topical stories. Here’s a collection of their appearances.
A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
The new TrumpRx program relies partly on connecting consumers with discount coupons offered by drugmakers. For insured patients, though, using a coupon can prove dicey.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
It may soon get easier for millions of people with Medicare to get discounted GLP-1 drugs for weight loss.
In “Hikma v. Amarin,” the Supreme Court’s decision could affect how quickly generic versions of brand-name medicines come to market.
An Arm and a Leg launches its “101” series with the story of Alfred Engelberg, a lawyer who’s been crusading to improve access to generic drugs by fixing loopholes in a law he helped draft more than 40 years ago.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
KFF Health News gives readers a chance to comment on a recent batch of stories.
So you’ve decided to go on a GLP-1 to lose weight. These medicines might seem like an easy way to drop unwanted pounds, but you’ll likely need to do a few other things to be successful long-term.
Some researchers and recovery advocates see the NET device as the latest in a series of products pitched as the solution to the addiction crisis that have been overhyped to capitalize on money from the opioid settlements.
HHS Secretary Robert F. Kennedy Jr. had another tough week. In addition to Kennedy having rotator cuff surgery, the nomination of his ally to become surgeon general is teetering, the controversial head of the FDA's vaccine center is resigning next month, and a new survey shows Americans trust government health officials less than they do former Biden official Anthony Fauci. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, and Shefali Luthra of The 19th join KFF Health News’ Julie Rovner to discuss these stories and more.
Diagnosed with an autoimmune disorder, a California man was prescribed a drug that costs thousands of dollars a month. He said he was reassured that the drugmaker’s copay card would cover his share, but after two months, the card was empty.
Robert F. Kennedy Jr. has criticized the broadening use of anxiety medications, claiming they’re harmful. Doctors and researchers say the MAHA movement is misrepresenting drugs that have been proved to safely treat chronic anxiety and point to broader social changes to explain their increased use.
Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are proposing bans.
It’s been a busy week at the FDA, with a political appointee overruling agency scientists to reject an application for a new flu vaccine. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Jackie Fortiér of KFF Health News, Lizzy Lawrence of Stat, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more.
© 2026 KFF